Previous 10 | Next 10 |
Gainers: Society Pass (NASDAQ:SOPA) +237%. Bluerock Residential Growth (NYSE:BRG) +71%. Can-Fite (NYSE:CANF) +59%. AeroClean (NASDAQ:AERC) +58%. Galera Therapeutics (NASDAQ:GRTX) +38%. Verso (NYSE:VRS) +35%. Roivant (NASDAQ:ROIV) +26%. Venus (NASDAQ:VERO) +25%. BioCardia (NASDAQ:BCDA) +1...
Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical nee...
Clarus Therapeutics (NASDAQ:CRXT) down 1.2% premarket after entering into an agreement to sell securities in a private placement with a leading healthcare investor. Expected gross proceeds are ~$15M. As per the agreement, Clarus will issue 3,024,194 units at a price of $4.96/unit. E...
Proceeds to support the ongoing commercialization of JATENZO ® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medica...
Clarus Therapeutics is a commercial stage pharmaceutical company advancing androgen replacement and metabolic therapies. The Company’s lead product JATENZO was FDA approved in March 2019 and commercially available in February 2020. The Company recently closed a business com...
Clarus Therapeutics Holdings (NASDAQ:CRXT) announces that the USPTO has issued two new patents for claims that cover Clarus’ oral testosterone replacement product, Jatenzo (testosterone undecanoate). Shares up 51.4% premarket at $7.89. Patent No. 11,179,403 entitled “O...
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list these patents in FDA’s Orange Book, which would bring the total num...
Gainers: MediciNova (NASDAQ:MNOV) +27%. Puma Biotechnology (NASDAQ:PBYI) +6%. GoHealth (NASDAQ:GOCO) +5%. Chindata Group Holdings Limited (NASDAQ:CD) +4%. Nutanix (NASDAQ:NTNX) +4%. Losers: Autodesk (NASDAQ:ADSK) -13%. Esperion Therapeutics (NASDAQ:ESPR) -10%. Cl...
Gainers: Pasithea KTTA +227%. Qualigen QLGN +102%. Petros Pharmaceuticals PTPI +85%. Aptevo APVO +75%. iSpecimen ISPC +45%. Clarus Therapeutics (NASDAQ:CRXT) +30%. Alzamend Neuro (NASDAQ:ALZN) +19%. Gracell GRCL +19%. Sunlands Technology Group STG +18%. Dyco...
When you look for different penny stocks to buy, what do you look for? In most cases, you’re seeking out a catalyst to understand why certain stocks might move or are in the process of moving. Today we focus on precisely that. Whether it’s stock market news, company-specific h...
News, Short Squeeze, Breakout and More Instantly...
Clarus Therapeutics Holdings Inc. Company Name:
CRXT Stock Symbol:
OTCMKTS Market:
Clarus Therapeutics Holdings Inc. Website:
Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXTQ), a pharmaceutical company dedicated to providing solutions to un...
NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary ...